Group 1 - The core point of the article is that Crystal Tech Holdings (02228) has completed the acquisition of Liverpool ChiroChem (LCC), enhancing its capabilities in the "AI + Robotics" autonomous experimental platform for chemical exploration [1] - Following the announcement, Crystal Tech Holdings' stock price increased by over 5%, reaching 6.08 HKD with a trading volume of 514 million HKD [1] - LCC, founded in 2014, specializes in the design and synthesis of novel chiral molecules and has developed the PACE technology platform that integrates AI and automation for efficient molecular screening and synthesis [1][2] Group 2 - LCC's extensive database of chiral chemical molecules is globally leading in molecular quality and diversity, providing high-quality data support for AI models in chiral molecular exploration [2] - LCC has a complete technical solution in high-throughput, micro-scale molecular library construction, complementing the large-scale molecular library technology of Crystal Tech Holdings' autonomous experimental platform [2]